Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Z-LEHD-FMK: Precision Caspase-9 Inhibition
2026-09-29
Z-LEHD-FMK helps separate caspase-9-dependent mitochondrial apoptosis from downstream executioner activity in cell, ischemia/reperfusion, cancer, and neuroprotection workflows. This guide combines time-resolved assay design, formulation guidance, orthogonal readouts, and troubleshooting for more interpretable apoptosis experiments.
-
When HRP Proximity Labeling Meets Serotonin
2026-09-29
Biotin-XX Tyramide Reagent enables membrane-impermeant HRP-mediated labeling of extracellular targets, but serotonin can suppress this chemistry in neuronal proximity-labeling workflows. This thought-leadership article connects the mechanistic finding to assay design, tyramide signal amplification, tissue imaging, and translational research strategy.
-
Cy3 Goat Anti-Mouse IgG (H+L) Antibody Workflow
2026-09-28
Build a reproducible fluorescence workflow around the Cy3 Goat Anti-Mouse IgG (H+L) Antibody for mapping RNLS–PMCA4b signaling in NCI-H295R cells. The guide connects receptor-localization imaging with flow cytometry, western blotting, and controls that distinguish fluorescence from true pathway effects.
-
SpCas9 mRNA: A Translation-Aware Editing Strategy
2026-09-28
SpCas9 mRNA enables guide-directed editing while separating Cas9 delivery from DNA-vector expression. This article explains how its RNA design shapes experimental interpretation—and why cap-independent translation research should not be confused with performance evidence for capped Cas9 mRNA.
-
RNA-Triggered Pyroptosis with Type III-E CRISPR
2026-09-27
The study introduces DAMAGE, a synthetic system that links target-RNA recognition by a type III-E CRISPR effector to gasdermin-mediated pyroptosis. Its findings establish a programmable strategy for eliminating selected transcriptome-altered cells, while leaving important questions about specificity, delivery, and therapeutic safety for further study.
-
Actinomycin D Workflows for RNA Stability
2026-09-26
Use Actinomycin D to separate altered mRNA decay from changes in transcription, with a practical chase design informed by diabetic vascular calcification research. This guide covers dose selection, solvent handling, controls, interpretation, and ways to limit confounding from transcriptional stress and cytotoxicity.
-
HR Repair Profiling Predicts Olaparib Sensitivity in MPM
2026-09-25
Borchert et al. combined cell-line drug-response experiments with gene-expression profiling of malignant pleural mesothelioma samples to investigate whether homologous recombination defects could indicate olaparib sensitivity. Their results support a BRCAness-based research hypothesis, particularly for BAP1-mutated cells, while emphasizing that gene-expression associations require further functional and clinical validation.
-
Targeted mRNA Therapy After Ischemic Stroke
2026-09-25
Gao and colleagues developed mannose receptor-targeted lipid nanoparticles to deliver IL-10-encoding mRNA to microglia in ischemic brain regions. In mouse stroke models, the approach promoted anti-inflammatory microglial responses, improved blood–brain barrier integrity, and reduced neurological injury, with reported benefit when treatment was initiated as late as 72 hours after stroke.
-
Azumiobodo hoyamushi: Drug Efficacy and Study Findings
2026-09-24
This study compared 20 drugs against Azumiobodo hoyamushi, the protozoan associated with soft tunic syndrome in cultured ascidians, and then tested selected treatments in experimentally infected animals. Fumagillin showed moderate in vitro activity, while formalin and chlorine dioxide reduced parasite numbers in tunic tissue after treatment; the results support further evaluation of disinfection approaches, not a validated farm-wide treatment.
-
Actinomycin D for mRNA Stability in TNBC
2026-09-24
Learn how Actinomycin D can help distinguish altered mRNA stability from transcriptional changes in TNBC research. This guide connects ActD chase design to the YTHDF3–CENPI findings while highlighting controls, interpretation limits, and practical handling.
-
TCAIM Tunes OGDH to Regulate Mitochondrial Metabolism
2026-09-23
A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that binds native OGDH and promotes its reduction through HSPA9 and LONP1. The resulting decrease in OGDH complex activity changes carbohydrate catabolism, revealing a protein-turnover mechanism for regulating mitochondrial metabolism.
-
Red Blood Cell Membrane Bending Rigidity
2026-09-23
The reference study isolates the red blood cell cytoplasmic membrane from the spectrin network and ATP-dependent effects to determine its intrinsic bending rigidity. By integrating X-ray diffuse scattering, neutron spin-echo spectroscopy, and molecular dynamics simulations, the authors estimate a relatively low bending modulus of approximately 4–6 kBT, clarifying why earlier whole-cell measurements varied so widely.
-
Avian Hair-Cell Ablation and Regeneration Protocol
2026-09-22
The reference paper presents an integrated workflow for inducing auditory hair-cell loss in young chickens and simultaneously assessing regenerative responses through multiplexed mRNA detection, immunohistochemistry, and EdU labeling. Its main contribution is methodological: it connects controlled inner-ear injury with spatial, protein-level, and cell-cycle readouts that can improve reproducibility in avian regeneration studies.
-
Temafloxacin Pharmacokinetics and Translational Limits
2026-09-22
The 1991 review of temafloxacin integrates oral and intravenous pharmacokinetics, distribution, elimination, renal function, and dosing implications into a clinically useful framework. Its high bioavailability, approximately 8-hour terminal half-life, and substantial unchanged urinary recovery support flexible dosing, while the healthy-volunteer design also defines important limits for extrapolation to other antimicrobial compounds.
-
Carbapenemase Gene Transmission in CREC, 2022–2024
2026-09-21
Chen et al. mapped carbapenemase-encoding genes, their genomic locations, transferability, and strain relatedness in carbapenem-resistant Enterobacter cloacae from eight Guangdong teaching hospitals. The findings emphasize plasmid-associated blaNDM-1, efficient horizontal dissemination, and the need to combine susceptibility testing with molecular surveillance and infection-control analysis.